Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, ameliorates hepatic fibrosis in rats with type 2 diabetes

Chinese Medical Journal

Volumn 127, Issue 2, 2014, Pages 225-231

  Zhou, Hong ^a   Fang, Cai Xia ^a   Zhang, Li Hui ^a   Deng, Yong Gui ^a   Wang, Mian ^a   Meng, Feng Ling ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Diabetes; Fasudil; Liver fibrosis; Rho kinase; Transforming growth factor 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; BETA ACTIN; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; FASUDIL; HYDROXYPROLINE; PROCOLLAGEN; TRANSFORMING GROWTH FACTOR BETA1; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; PROTEIN KINASE INHIBITOR; RHO KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HISTOLOGY; INSULIN RESISTANCE; LIVER FIBROSIS; LIVER FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; ENZYMOLOGY; LIVER CIRRHOSIS; METABOLISM; SPRAGUE DAWLEY RAT;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CONNECTIVE TISSUE GROWTH FACTOR; DIABETES MELLITUS, TYPE 2; FEMALE; LIVER CIRRHOSIS; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84892570134     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20131917     Document Type: Article

References (33)

1. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27-38.
2. Cusi K. Non-alcoholic fatty liver disease in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2009; 16: 141-149.
3. Musso G, Gambing R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010; 11: 430-445.
4. Rivera CA. Risk factors and mechanisms of non-alcoholic steatohepatitis. Pathophysiology 2008; 15: 109-114.
5. Qiang G, Zhang L, Yang X, Xuan Q, Shi L, Zhang H, et al. Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes. Eur J Pharmacol 2012; 685: 156-164.
6. Lo L, McLennan SV, Williams PF, Bonner J, Chowdhury S, McCaughan GW, et al. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J Hepatol 2011; 55: 435-444.
7. Sugimoto R, Enjoji M, Kohjima M, Tsuruta S, Fukushima M, Iwao M, et al. High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation of mitogen-activated protein kinase. Liver Int 2005: 25: 1018-1026.
8. Iwamoto K, Kanno K, Hyogo H, Yamagishi S, Takeuchi M, Tazuma S, et al. Advanced glycation and products enhance the proliferation and activation of hepatic stellate cells. Gastroenterol 2008; 43: 298-304.
9. Yokogawa K, Matsui-Yuasa I, Tamura A, Terada M, Kojima-Yuasa A. Inhibitory effects of ecklonia cava extract on high glucose-induced hepatic stellate cell activation. Mar Drugs 2011; 9: 2793-2808.
10. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003; 4: 446-456.
11. Rajagopalan LE, Davies MS, Kahn LE, Kornmeier CM, Shimada H, Steiner TA, et al. Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activity. J Pharmacol Exp Ther 2010; 333: 707-716.
12. Zhou H, Zhang KX, Li YJ, Guo BY, Wang M, Wang M. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses high glucose-induced proliferation and collagen synthesis in rat cardiac fibroblasts. Clin Exp Pharmacol Physiol 2011; 38: 387-394.
13. Rikitake Y, Liao JK. Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation 2005; 111: 3261-3268.
14. Zhou H, Li YJ. RhoA/Rho kinase: a novel therapeutic target in diabetic complicatins. Chin Med J 2010; 123: 2461-2466.
15. Zhou H, Li YJ. Rho kinase inhibitors: potential treatments for diabetes and diabetic complications. Curr Pharm Des 2012; 18: 2964-2973.
16. Fukushima M, Nakamuta M, Kohjima M, Kotoh K, Enjoji M, Kobayashi N, et al. Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. Liver Int 2005; 25: 829-838.
17. Kitamura K, Tada S, Nakamoto N, Toda K, Horikawa H, Kurita S, et al. Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis. J Gastroenterol Hepatol 2007; 22: 2022-2033.
18. Murata T, Arii S, Mori A, Imamura M. Therapeutic significance of Y-27632, a Rho-kinase inhibitor, on the established liver fibrosis. J Surg Res 2003;114: 64-71.
19. Zhou H, Li YJ, Wang M, Zhang LH, Guo BY, Zhao ZS, et al. Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes. Acta Pharmacol Sin 2011; 32: 999-1008.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
21. Tran TT, Gupta N, Goh T, Naigamwalla D, Chia MC, Koohestani N, et al. Direct measure of insulin sensitivity with the hyperinsulinemic-euglycemic clamp and surrogate measures of insulin sensitivity with the oral glucose tolerance test: correlations with aberrant crypt foci promotion in rats. Cancer Epidemiol Biomarkers Prev 2003; 12: 47-56.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods 2001; 25: 402-408.
23. Wakino S, Hayashi K, Kanda T, Tatematsu S, Homma K, Yoshioka K, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ Res 2004; 95: e45-e55.
24. Tanaka S, Hayashi T, Toyoda T, Hamada T, Shimizu Y, Hirata M, et al. High-fat diet impairs the effects of a single bout of endurance exercise on glucose transport and insulin sensitivity in rat skeletal muscle. Metabolism 2007; 56: 1719-1728.
25. Flanagan AM, Brown JL, Santiago CA, Aad PY, Spicer LJ, Spicer MT. High-fat diets promote insulin resistance through cytokine gene expression in growing female rats. J Nutr Biochem 2008; 19: 505-513.
26. Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis 2007; 11: 105-117.
27. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
28. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008; 57: 714-723.
29. Peng F, Wu D, Gao B, Ingram AJ, Zhang B, Chorneyko K, et al. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 2008; 57: 1683-1692.
30. Mann DA, Smart DE. Transcriptional regulation of hepatic stellate cell activation. Gut 2002; 50: 891-896.
31. Iwamoto H, Nakamuta M, Tada S, Sugimoto R, Enjoji M, Nawata H. A p160ROCK-specic inhibitor, Y-27632, attenuates rat hepatic stellate cell growth. J Hepatol 2000; 32: 762-770.
32. Murata T, Arii S, Nakamura T, Mori A, Kaido T, Furuyama H, et al. Inhibitory effect of Y-27632, a ROCK inhibitor, on progression of rat liver fibrosis in association with inactivation of hepatic stellate cells. J Hepatol 2001; 35: 474-481.
33. Tada S, Iwamoto H, Nakamuta M, Sugimoto R, Enjoji M, Nakashima Y, et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic brosis in rats. J Hepatol 2001; 34: 529-936.